Check the measurement
QC / analytical lead
Confirm source results, method version, standards and instrument performance. Review B-126 when its result becomes available.
Every batch can pass.The process can still shift.
Continued process verification across your batch and lab records. Ask neil to review the trend and prepare the next steps.
Bring a process to review
Assay across 24 reviewed batches
Assay · % label claim10510095
B-101B-117 → B-124
All results meet specification. Anything to review?
neil
Yes. The last 8 results are all above the reference.
That triggers this plan’s review rule. Passing the specification doesn’t clear the signal.
Which records are included?
24 reviewed results from recipe v09. One result is pending and one batch uses v10; neither is plotted. Both remain in the source list.
What changed? Prepare the review for MSAT and Quality.
neil
The material lot changes at the same point as the higher results. That gives us a lead—not a cause. I’d check the measurement and compare the process context before drawing a conclusion.
What should each team do next?
Investigate the shared context
MSAT / process owner
MAT-B appears with the eight higher results. Compare material attributes, process conditions and relevant events. The timing alone does not establish a material effect.
Agree the next monitoring window
CPV lead / Quality
Document the signal assessment, any required investigation and the next review. Keep recipe v10 separate unless pooling is scientifically justified. Do not move the reference simply to clear the signal.
A trend is only useful if you can explain what went into it.
Bring manufacturing context, analytical results and quality events into the same review. Keep the link to each source.
Batch context
Orders, material lots and the production version.
Analytical results
Samples, method versions, units and result status.
Quality context
Deviations, changes and supporting documents.
The review should lead somewhere.
Keep the finding, the response and the next review connected. A signal is the start of a decision—not a conclusion about its cause.
Investigate the signal
Carry the affected batches and source evidence into the investigation.
InvestigationControl the response
Assess proposed process or monitoring changes before putting them into use.
Change controlReview the outcome
Bring the reviewed analysis and outstanding work into the product review.
APQRQuestions from CPV teams.
For the underlying lifecycle approach, see FDA’s Process Validation guidance, Stage 3 ↗.
Batch release and CPV answer different questions. A result can meet its specification while a series changes over time. CPV reviews process performance and variation across a defined population; authorised reviewers still make product and process decisions.
No. The example specification is 95–105% label claim. Its fixed monitoring reference is 100%, with an illustrative eight-result rule. The reference is not a statistically estimated control limit. Your team selects and verifies the appropriate limits, methods and signal rules for the real process.
No. The chart, replies and review use fictional, fixed example records. The calculations operate on those records; no laboratory or manufacturing system is queried. The example does not establish process control, root cause or batch approval.
Yes. Scope the records, time basis, units, process phases and version references for each connection. Permitted source data or supplied exports can form the review population. Connections depend on the source API, configuration and access.
Keep expected records visible, even when an analysis cannot include them. The example separates one pending result and one different process version from its 24 reviewed results. Your monitoring plan defines completeness, inclusion, exclusion and comparability; missing is never silently converted to zero.
Ask neil to prepare the dataset, proposed method, calculations and interpretation for review. Your qualified team verifies assumptions, population, limits and implementation before using them for CPV decisions. This small demonstration deliberately does not report Cp or Cpk or claim a qualified control chart.
Keep the reviewed population, analysis definition, findings, linked investigations and open work with the periodic review. A later dataset or method revision should not silently replace the evidence behind an earlier conclusion.